TipRanks - 2025-06-04 12:40
B. Riley analyst Yuan Zhi reiterates a Buy rating on Hyperfine (HYPR) with a $1 price target after the company’s premium Swoop received FDA 510k approval weeks ahead of schedule. The new next-generation MRI system includes a new scanner and Optive artificial intelligence software, producing the highest level of image quality and uniformity, the analyst tells investors in a research note. The firm says Hyperfine kept the hardware development confidential up until yesterday, so it is likely not on
